Processa Pharmaceuticals Inc (PCSA)

$0.31 +0.00 (1.21%)
Market Cap 15.43M
Revenue (ttm) 0.00
Net Income (ttm) -11.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 4,602,900
Avg Vol 11,400,026
Day's Range N/A - N/A
Shares Out 50.35M
Stochastic %K 24%
Beta 1.53
Analysts Sell
Price Target $1.00

Company Profile

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical t...

Industry: Biotechnology
Sector: Healthcare
Phone: 443 776 3133
Fax: 443 288 4420
Address:
7380 Coca Cola Drive, Suite 106, Hanover, United States
jesusatemylunch
jesusatemylunch Oct. 25 at 3:25 AM
$PCSA The classy move is a Colecovision
0 · Reply
frchmn
frchmn Oct. 24 at 10:10 PM
$PCSA also an unrelated question: how do you handle your anxiety?
4 · Reply
HedgeFundBro
HedgeFundBro Oct. 24 at 8:10 PM
$PCSA ladies and gentlemen I have an question but it’s not about PCSA. I’m asking here because I trust most of you and I’m bored with this chart rn. Should I buy Ps5 or Xbox X
4 · Reply
ckjamesst
ckjamesst Oct. 24 at 5:42 PM
$PCSA after hours we popping harder
1 · Reply
NIVOLOCO
NIVOLOCO Oct. 24 at 5:42 PM
$PCSA 🔥
0 · Reply
TheDrunkTrader69
TheDrunkTrader69 Oct. 24 at 5:11 PM
$PCSA Got that dip can we get our rip?
0 · Reply
notsurewhat
notsurewhat Oct. 24 at 4:55 PM
$PCSA
0 · Reply
damnbruh
damnbruh Oct. 24 at 4:41 PM
$PCSA slap the ask no walls holding us
0 · Reply
yankeeslugger99
yankeeslugger99 Oct. 24 at 4:31 PM
$PCSA
0 · Reply
ckjamesst
ckjamesst Oct. 24 at 3:41 PM
$PCSA fly baby fly
0 · Reply
Latest News on PCSA
Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies

Aug 7, 2025, 8:30 AM EDT - 2 months ago

Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies

Processa Pharmaceuticals Provides Portfolio and Business Update

Jul 1, 2025, 9:00 AM EDT - 4 months ago

Processa Pharmaceuticals Provides Portfolio and Business Update

Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering

Jun 17, 2025, 12:26 PM EDT - 4 months ago

Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering

Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate

Jun 17, 2025, 9:00 AM EDT - 4 months ago

Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate

Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025

Jun 13, 2025, 8:00 AM EDT - 4 months ago

Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025

Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting

May 30, 2025, 9:00 AM EDT - 5 months ago

Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting

Processa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025

Apr 15, 2025, 8:00 AM EDT - 6 months ago

Processa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

Mar 18, 2025, 8:30 AM EDT - 7 months ago

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

Feb 7, 2025, 8:00 AM EST - 9 months ago

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Jan 30, 2025, 5:17 PM EST - 9 months ago

Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Jan 27, 2025, 8:30 PM EST - 9 months ago

Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer

Oct 2, 2024, 4:05 PM EDT - 1 year ago

Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer

Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September

Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer

Jun 11, 2024, 8:20 AM EDT - 1 year ago

Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer

Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference

May 6, 2024, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference

Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research

Apr 30, 2024, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research

Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting

Mar 25, 2024, 8:15 AM EDT - 1 year ago

Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting

Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Feb 21, 2024, 8:15 AM EST - 1 year ago

Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference

Feb 14, 2024, 1:00 PM EST - 1 year ago

Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference

Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 6, 2024, 8:30 AM EST - 1 year ago

Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering

Feb 1, 2024, 4:22 PM EST - 1 year ago

Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering

Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

Jan 26, 2024, 9:04 AM EST - 1 year ago

Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

What made Processa Pharmaceuticals stock nearly triple on Thursday?

Jan 25, 2024, 11:29 AM EST - 1 year ago

What made Processa Pharmaceuticals stock nearly triple on Thursday?

Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses

Jan 25, 2024, 8:30 AM EST - 1 year ago

Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses

Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

Jan 19, 2024, 7:45 AM EST - 1 year ago

Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split

Jan 18, 2024, 7:45 AM EST - 1 year ago

Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split

Processa Pharmaceuticals to Present at the Biotech Showcase 2024

Jan 2, 2024, 5:06 PM EST - 1 year ago

Processa Pharmaceuticals to Present at the Biotech Showcase 2024

Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine

Dec 19, 2023, 9:00 AM EST - 2 years ago

Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine

Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine

Dec 13, 2023, 9:00 AM EST - 2 years ago

Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine

Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference

Nov 30, 2023, 8:15 AM EST - 2 years ago

Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference

Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook

Nov 29, 2023, 8:15 AM EST - 2 years ago

Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook

Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson

Nov 13, 2023, 1:40 PM EST - 2 years ago

Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson

Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas

Nov 9, 2023, 8:15 AM EST - 2 years ago

Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas

Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders

Nov 1, 2023, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders

Processa Pharmaceuticals to Present at the ThinkEquity Conference

Oct 13, 2023, 1:08 PM EDT - 2 years ago

Processa Pharmaceuticals to Present at the ThinkEquity Conference

Processa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Processa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer Care

Aug 17, 2023, 8:05 AM EDT - 2 years ago

Processa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer Care

Processa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual Conference

Aug 10, 2023, 4:15 PM EDT - 2 years ago

Processa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual Conference

Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer

Aug 8, 2023, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer

Next Generation Chemotherapy: Improved Treatment for More Patients

Jun 14, 2023, 4:15 PM EDT - 2 years ago

Next Generation Chemotherapy: Improved Treatment for More Patients

Processa Pharmaceuticals to Participate in a Panel on Interaction with the FDA at the World Orphan Drug Congress

May 22, 2023, 8:05 AM EDT - 2 years ago

Processa Pharmaceuticals to Participate in a Panel on Interaction with the FDA at the World Orphan Drug Congress

Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative

May 18, 2023, 8:00 AM EDT - 2 years ago

Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative

Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual Meeting

Apr 28, 2023, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual Meeting

Processa Pharmaceuticals, Inc. (PCSA) Q4 2022 Earnings Call Transcript

Mar 31, 2023, 4:14 PM EDT - 2 years ago

Processa Pharmaceuticals, Inc. (PCSA) Q4 2022 Earnings Call Transcript

Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results

Mar 30, 2023, 4:01 PM EDT - 2 years ago

Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results

Processa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. EST

Mar 23, 2023, 8:30 AM EDT - 2 years ago

Processa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. EST

Processa Pharmaceuticals Announces First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine

Mar 17, 2023, 8:30 AM EDT - 2 years ago

Processa Pharmaceuticals Announces First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine

Processa Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Mar 7, 2023, 8:30 AM EST - 2 years ago

Processa Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Processa Pharmaceuticals Announces Prioritization on Development of Next Generation Chemotherapies

Feb 21, 2023, 8:30 AM EST - 2 years ago

Processa Pharmaceuticals Announces Prioritization on Development of Next Generation Chemotherapies

Processa Pharmaceuticals, Inc. Announces Closing of $6.25 Million Registered Direct Offering, Which Included Retail Investors and Insiders, Priced at the Market Under Nasdaq Rules

Feb 15, 2023, 8:30 AM EST - 2 years ago

Processa Pharmaceuticals, Inc. Announces Closing of $6.25 Million Registered Direct Offering, Which Included Retail Investors and Insiders, Priced at the Market Under Nasdaq Rules

jesusatemylunch
jesusatemylunch Oct. 25 at 3:25 AM
$PCSA The classy move is a Colecovision
0 · Reply
frchmn
frchmn Oct. 24 at 10:10 PM
$PCSA also an unrelated question: how do you handle your anxiety?
4 · Reply
HedgeFundBro
HedgeFundBro Oct. 24 at 8:10 PM
$PCSA ladies and gentlemen I have an question but it’s not about PCSA. I’m asking here because I trust most of you and I’m bored with this chart rn. Should I buy Ps5 or Xbox X
4 · Reply
ckjamesst
ckjamesst Oct. 24 at 5:42 PM
$PCSA after hours we popping harder
1 · Reply
NIVOLOCO
NIVOLOCO Oct. 24 at 5:42 PM
$PCSA 🔥
0 · Reply
TheDrunkTrader69
TheDrunkTrader69 Oct. 24 at 5:11 PM
$PCSA Got that dip can we get our rip?
0 · Reply
notsurewhat
notsurewhat Oct. 24 at 4:55 PM
$PCSA
0 · Reply
damnbruh
damnbruh Oct. 24 at 4:41 PM
$PCSA slap the ask no walls holding us
0 · Reply
yankeeslugger99
yankeeslugger99 Oct. 24 at 4:31 PM
$PCSA
0 · Reply
ckjamesst
ckjamesst Oct. 24 at 3:41 PM
$PCSA fly baby fly
0 · Reply
SteveStachion
SteveStachion Oct. 24 at 3:31 PM
$PCSA $BURU my two .30 cent negative nellys are alive and well. Glad i held thru the storm, knew we would spin around. Not selling a damn thing.
0 · Reply
NIVOLOCO
NIVOLOCO Oct. 24 at 3:31 PM
$PCSA 🔥
0 · Reply
luminouslumens
luminouslumens Oct. 24 at 3:18 PM
$PCSA $AZTR Top watches going into AH 🧐
0 · Reply
HedgeFundBro
HedgeFundBro Oct. 24 at 3:15 PM
$PCSA someone knows something that we don’t.
0 · Reply
ckjamesst
ckjamesst Oct. 24 at 3:10 PM
$PCSA this is the bottom boys buy it up
0 · Reply
Mongo28
Mongo28 Oct. 24 at 3:07 PM
$PCSA Here we go baby !!!
0 · Reply
damnbruh
damnbruh Oct. 24 at 3:03 PM
$PCSA free path to $0.5
1 · Reply
ASTS11
ASTS11 Oct. 24 at 2:48 PM
$PCSA
0 · Reply
Bedlam03
Bedlam03 Oct. 24 at 2:48 PM
$PCSA on a Friday? Ok.
1 · Reply
TheDrunkTrader69
TheDrunkTrader69 Oct. 24 at 2:44 PM
$PCSA .35 wall is coming down
1 · Reply
frchmn
frchmn Oct. 24 at 2:34 PM
$PCSA ones who got in @ <= .3
0 · Reply
TheDrunkTrader69
TheDrunkTrader69 Oct. 24 at 2:00 PM
$PCSA
0 · Reply